RECOVERY & TISSUE REPAIR / MATRIX
Three compounds, three different evidence bases
How a fragment, a tripeptide and a four-peptide blend differ in mechanism, what has actually been tested, and what each one's biggest open question is.
The short version
This page lines up TB-500, KPV and KLOW on the dimensions that matter when reading recovery-and-repair peptide research: mechanism, what has actually been studied, regulatory and doping status, and the single biggest caution for each. The short version: all three are studied for tissue-repair biology relevant to hard-training recovery, but their evidence bases are genuinely different in kind, not just in size. TB-500's strongest data belong to a different molecule (full-length thymosin beta-4). KPV's entire efficacy record is preclinical. KLOW's four-peptide combination has never been tested as a unit at all. None of this is medical advice, and no dose is recommended anywhere on this site.
The comparison matrix
| Dimension | TB-500 | KPV | KLOW |
|---|---|---|---|
| What it is | Synthetic Ac-LKKTETQ fragment of thymosin beta-4 (7 amino acids) | Synthetic tripeptide, C-terminal fragment of alpha-MSH (3 amino acids) | Four-peptide co-formulation: KPV + GHK-Cu + BPC-157 + TB-500 in one vial |
| Proposed mechanism | Actin sequestration, driving cell migration and angiogenesis [3][5] | PepT1-mediated uptake, NF-κB/MAPK suppression [8] | Combines cytokine, matrix, vascular and cytoskeletal mechanisms from its four components |
| Human data | Phase 1 IV safety study, but of the full-length protein, not the fragment [4] | None published for any indication | None for the blend; a 2-person IV pilot exists for BPC-157 alone [13] |
| Animal data | Stroke, wound and cardiac-repair models, mostly with full-length protein [1][2][3] | Mouse colitis models only [6][7][8][9] | None for the blend; each component studied separately |
| Regulatory / doping status | Not FDA-approved; WADA-prohibited [1] | Not FDA-approved; no drug or supplement status | Not FDA-approved; WADA implications via its TB-500 component [1] |
| Key caution | Fragment ≠ full-length protein the data was built on [1][3] | Zero human trials; efficacy is entirely preclinical [8][9] | The combination itself has never been tested; PK mismatch between components [1][13] |
What each one is
TB-500 and KPV are both fragments of larger natural proteins, but they occupy very different sizes and roles. TB-500 is seven amino acids, cut from a 43-amino-acid protein (thymosin beta-4) best known for actin-binding biology relevant to cell movement and blood-vessel growth [3][5]. KPV is smaller still — three amino acids — cut from the tail end of alpha-MSH, retaining that hormone's anti-inflammatory activity while dropping its effect on pigmentation entirely [10]. KLOW is different in kind rather than degree: it is not a fragment of anything, but a co-dissolved mixture of TB-500, KPV and two further peptides (GHK-Cu and BPC-157) sold together in one research vial [1].
Evidence base
This is where the three genuinely separate. TB-500's literature is a mix of animal injury and stroke models plus one human Phase 1 safety study — but the human study and most of the striking animal results used full-length thymosin beta-4, not the short fragment sold commercially, an identity gap the corpus flags repeatedly [1][2][3][4]. KPV's entire efficacy record sits in cell culture and mouse colitis studies; there is no human trial of any kind [6][7][8][9]. KLOW inherits component-level evidence from all four of its ingredients but has zero direct evidence of its own — no study has compared the blend to monotherapy, to a subset of its components, or to placebo [1][13][14].
Regulatory and doping status
None of the three is an FDA-approved medicine or dietary supplement; all are sold strictly as research chemicals for laboratory use. TB-500 (as thymosin beta-4) is explicitly named on the World Anti-Doping Agency's prohibited list, and anti-doping labs have developed detection methods for it and its breakdown products [1][4]. KPV carries no specific WADA classification, though as an unapproved peptide it warrants the same caution in any tested-athlete context. Because KLOW contains TB-500, the blend inherits the same WADA implications as TB-500 alone [1].
Key caution
Each compound has a defining caveat worth carrying forward. For TB-500, it is the identity gap: the fragment sold commercially is not the same molecule as the full-length protein behind most of the encouraging data, and it has not been shown that the fragment reproduces those effects [1][3]. For KPV, it is simply the total absence of human evidence — every finding described on this site comes from cells or mice, and dosing, efficacy and safety in people are all unestablished [8][9]. For KLOW, it is the untested combination itself, compounded by a structural pharmacokinetic mismatch — the tripeptide components clear far faster than BPC-157, so a single vial cannot plausibly hold all four peptides at matched exposures, making every synergy claim an extrapolation rather than a demonstrated result [1][13].